ERBB2 and cancer: Additional tumor characteristics commonly associated with aggressive clinical behavior in breast cancer, such as positivity for Ki67 and HER2/neu, were associated with incident-detected cancers, which supports the hypothesis that incident cancers are biologically more aggressive than their prevalent screen-detected counterparts.